the new crown vaccine jointly developed by Oxford University and AstraZeneca

Oxford new crown vaccine approved in the UK

According to a BBC report on December 30, the British drug regulatory agency approved the new crown vaccine jointly developed by Oxford University and AstraZeneca.

According to the previously announced Phase III clinical trial results, the average effectiveness of the vaccine reached 70%. Berichten zufolge, the British government has ordered 100 million doses of Oxford vaccine from AstraZeneca, enough to vaccinate 50 million people.

Will the vaccine sector rise again?

The Oxford-AstraZeneca Covid-19 vaccine was approved by the British Medicines and Healthcare Products Administration (MHRA) on the 30th and will be officially put into clinical use for mass vaccination. This is the second new crown vaccine approved by the United Kingdom after Pfizer vaccine in the United States.

British Prime Minister Boris Johnson immediately tweeted that day, “This is great news and a victory for British science. Now we will act as soon as possible to vaccinate as many people as possible.” British Health Minister Matthew Hancock told the media, „This is a truly important moment, a true British success story.“ Hancock said that the Oxford vaccine will be put into use on January 4. The Medical Service System (NHS) will carry out mass vaccination at its fastest speed. The vaccine will provide a way for the UK to get rid of the new crown epidemic by next spring, when millions of vulnerable people will be protected. British Chief Medical Officer Chris Whitty praised, „A considerable collective effort has brought us to this point, paying tribute to British scientists.

British media rushed to report, saying that the UK ushered in the most exciting good news at the end of 2020. The British Broadcasting Corporation (BBC) said that the Oxford vaccine was approved for use in the United Kingdom, which is a landmark moment and will lead the United Kingdom to achieve a large-scale „immunization campaign“ zu „return life to normal“. Die „Sonne“ described the Oxford vaccine as the „hope“ of the United Kingdom in the title of the article, und das „Guardian“ called the Oxford vaccine „critical.“

According to Hancock, the test results show that the Oxford vaccine developed by the University of Oxford in the United Kingdom and AstraZeneca in the United Kingdom has an average effectiveness of 70%. The effectiveness of the two doses of vaccination is 62% und 90%, bzw. The recommended interval between the second dose is 12 Wochen. It is „very helpful“ for more people to get immunity through the first dose. Im Gegensatz, Oxford vaccines are cheaper than other vaccines, are easy to mass produce, can be stored in ordinary refrigerators, and are easier to transport to nursing homes and general clinics.

Derzeit, the British government has ordered 100 million doses of Oxford vaccine, enough to vaccinate 50 million people, who make up about 73% of the British population.